Trial with laquinimod in primary progressive MS fails...

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Trial with laquinimod in primary progressive MS fails...

Post by MSUK » Mon Dec 04, 2017 6:48 am

Phase II trial with laquinimod in primary progressive MS fails to deliver

Active Biotech drug, laquinimod has failed a phase II trial in primary progressive MS.

Laquinimod a once-daily oral drug targets neurodegeneration and inflammation with a novel mechanism of action being developed for the treatment of relapsing remitting MS (RRMS), primary-progressive MS (PPMS) and Huntington disease...Read more - http://www.ms-uk.org/phase-ii-trial-laq ... ls-deliver

Image
MS-UK - http://www.ms-uk.org/

User avatar
jimmylegs
Volunteer Moderator
Posts: 12076
Joined: Sat Mar 11, 2006 3:00 pm

Re: Trial with laquinimod in primary progressive MS fails...

Post by jimmylegs » Tue Dec 05, 2017 5:24 am

Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS
http://www.activebiotech.com/press-rele ... id=2153402

PRESS RELEASE

Active Biotech (Nasdaq Stockholm: ACTI) today announced initial results from the Phase II proof of concept study of laquinimod in Primary Progressive MS (PPMS) sponsored by Active Biotech's partner Teva Pharmaceuticals Industries Ltd. The primary endpoint of brain atrophy as defined by percent brain volume change (PBVC) from baseline to week 48, was not met after daily oral doses with 0.6 mg laquinimod.

The secondary endpoint of time to confirmed disability progression was also not met. There was, however, a reduction in new T2 lesions observed in patients treated with laquinimod 0.6 mg.

The clinical safety profile of laquinimod 0.6 mg daily in PPMS patients resembled the safety profile demonstrated in relapsing remitting MS patients. The most common adverse events reported by patients treated with laquinimod 0.6 mg daily were nasopharyngities, headache, upper respiratory tract infection and back pain.

Data from the trial will be presented at a future scientific conference and the full results will be published.
take control of your own health
pursue optimal self care at least as actively as a diagnosis
ask for referrals to preventive health care specialists eg dietitians
don't let suboptimal self care muddy any underlying diagnostic picture!

Post Reply
  • Similar Topics
    Replies
    Views
    Last post